Search

Your search keyword '"Mitjavila, F."' showing total 3 results
Start Over Author "Mitjavila, F." Topic immunology
3 results on '"Mitjavila, F."'

1. First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort

Author

Ruiz-Irastorza, G., Garcia, M., Espinosa, G., Caminal, L., Mitjavila, F., Gonzalez-Leon, R., Sopena, B., Canora, J., Villalba, M. V., Rodriguez-Carballeira, M., Lopez-Dupla, J. M., Callejas, J. L., Castro, A., Tolosa, C., Sanchez-Garcia, M. E., Perez-Conesa, M., Navarrete-Navarrete, N., Rodriguez, A. P., Herranz, M. T., Pallares, L., RELES, Autoimmune Dis Study Grp GEAS, [Ruiz-Irastorza, G.] Univ Basque Country, Autoimmune Dis Res Unit, Dept Internal Med, BioCruces Hlth Res Inst,Hosp Univ Cruces, Baracaldo, Bizkaia, Spain, [Garcia, M.] Univ Basque Country, Autoimmune Dis Res Unit, Dept Internal Med, BioCruces Hlth Res Inst,Hosp Univ Cruces, Baracaldo, Bizkaia, Spain, [Espinosa, G.] Hosp Clin Barcelona, Dept Autoimmune Dis, Barcelona, Spain, [Caminal, L.] Hosp Univ Cent Asturias, Dept Internal Med, Oviedo, Asturias, Spain, [Mitjavila, F.] Hosp Univ Bellvitge, Dept Internal Med, Autoimmune Dis Unit, Barcelona, Spain, [Gonzalez-Leon, R.] Hosp Univ Virgen del Rocio, Dept Internal Med, Seville, Spain, [Sopena, B.] Complejo Hosp Univ Vigo, Dept Internal Med, Vigo, Spain, [Canora, J.] Hosp Univ Fuenlabrada, Dept Internal Med, Madrid, Spain, [Villalba, M. V.] Hosp Gen Univ Gregorio Maranon, Dept Internal Med, Madrid, Spain, [Rodriguez-Carballeira, M.] Hosp Univ Mutua Terrasa, Dept Internal Med, Barcelona, Spain, [Lopez-Dupla, J. M.] Hosp Univ Joan XXIII, Dept Internal Med, Tarragona, Spain, [Callejas, J. L.] Hosp Univ San Cecilio, Dept Internal Med, Granada, Spain, [Castro, A.] Hosp Univ St Joan de Reus, Dept Internal Med, Tarragona, Spain, [Tolosa, C.] Corporacio Sanitaria Parc Tauli, Dept Internal Med, Barcelona, Spain, [Sanchez-Garcia, M. E.] Hosp Univ Reina Sofia, Dept Internal Med, Autoimmune Dis Unit, Cordoba, Spain, [Perez-Conesa, M.] Hosp Univ Miguel Servet, Dept Internal Med, Zaragoza, Spain, [Navarrete-Navarrete, N.] Hosp Univ Virgen de las Nieves, Dept Internal Med, Granada, Spain, [Rodriguez, A. P.] Complejo Hosp Univ Ourense, Dept Internal Med, Orense, Spain, [Herranz, M. T.] Hosp JM Morales Meseguer, Dept Internal Med, Murcia, Spain, [Pallares, L.] Hosp Univ Son Espases, Dept Internal Med, Islas Baleares, Spain, Spanish Society of Internal Medicine, RELES, Autoimmune Diseases Study Group (GEAS), [Ruiz-Irastorza,G, Garcia,M] Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Bizkaia, Spain. [Espinosa,G] Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain. [Caminal,L] Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Asturias , Spain. [Mitjavila,F] Autoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. [González-León,R] Department of Internal Medicine , Hospital Universitario Virgen del Rocío, Sevilla, Spain. [Sopeña,B] Department of Internal Medicine, Complejo Hospitalario Universitario de Vigo, Pontevedra, Vigo , Spain. [Canora,J] Department of Internal Medicine, Hospital Universitario Fuenlabrada, Fuenlabrada, Madrid , Spain. [Villalba,MV] Department of Internal Medicine, Hospital General Universitario Gregorio Marañón, Madrid, Spain. [Rodríguez-Carballeira,M] Department of Internal Medicine, Hospital Universitario Mutua de Terrasa, Barcelona, Spain. [López-Dupla,JM] Department of Internal Medicine, Hospital Universitario Joan XXIII, Tarragona, Spain. [Callejas,JL] Department of Internal Medicine, Hospital Universitario San Cecilio, Granada, Spain. [Castro,A] Department of Internal Medicine, Hospital Universitario Sant Joan de Reus, Reus, Tarragona , Spain. [Tolosa,C] Department of Internal Medicine, Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain. [Sánchez-García,ME] Department of Internal Medicine, Autoimmune Diseases Unit, Hospital Universitario Reina Sofía , Córdoba, Spain. [Pérez-Conesa,M] Department of Internal Medicine, Hospital Universitario Miguel Servet, Zaragoza, Spain. [Navarrete-Navarrete,N] Department of Internal Medicine , Hospital Universitario Virgen de las Nieves, Granada, Spain. [Rodríguez,AP] Department of Internal Medicine, Complejo Hospitalario Universitario de Ourense, Ourense, Spain. [Herranz,MT] Department of Internal Medicine, Hospital J.M. Morales Meseguer, Murcia, Spain. [Pallarés,L] Department of Internal Medicine, Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain., and This study was supported by the Spanish Society of Internal Medicine.

Subjects
0301 basic medicine, Lupus nephritis, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, immune system diseases, Prednisone, Nefritis lúpica, Phenomena and Processes::Circulatory and Respiratory Physiological Phenomena::Cardiovascular Physiological Phenomena::Hemodynamics::Pulse [Medical Subject Headings], skin and connective tissue diseases, Diseases::Skin and Connective Tissue Diseases::Connective Tissue Diseases::Lupus Erythematosus, Cutaneous::Lupus Erythematosus, Discoid [Medical Subject Headings], Systemic lupus erythematosus, Lupus eritematoso discoide, Cumulative dose, General Medicine, Humanos, Chemicals and Drugs::Polycyclic Compounds::Steroids::Pregnanes::Pregnadienes::Pregnadienetriols::Prednisolone::Methylprednisolone [Medical Subject Headings], Cohort, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors::Immunosuppressive Agents [Medical Subject Headings], Glucocorticoid, medicine.drug, medicine.medical_specialty, Antimaláricos, Immunology, Diseases::Skin and Connective Tissue Diseases::Connective Tissue Diseases::Lupus Erythematosus, Systemic::Lupus Nephritis [Medical Subject Headings], Brief Communication, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiparasitic Agents::Antiprotozoal Agents::Antimalarials [Medical Subject Headings], Systemic Lupus Erythematosus, Disease activity, 03 medical and health sciences, Internal medicine, Lupus eritematoso sistémico, medicine, Corticosteroids, Metilprednisolona, Glucocorticoides, Disease Activity, 030203 arthritis & rheumatology, business.industry, Diseases::Skin and Connective Tissue Diseases::Connective Tissue Diseases::Lupus Erythematosus, Systemic [Medical Subject Headings], Inmunosupresores, Pulso arterial, medicine.disease, Chemicals and Drugs::Polycyclic Compounds::Steroids::Pregnanes::Pregnadienes::Pregnadienediols::Prednisone [Medical Subject Headings], Chemicals and Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Adrenal Cortex Hormones::Glucocorticoids [Medical Subject Headings], 030104 developmental biology, Endocrinology, Prednisona, Observational study, business
Abstract

Aim: To study the influence of prednisone dose during the first month after systemic lupus erythematosus (SLE) diagnosis (prednisone-1) on glucocorticoid burden during the subsequent 11 months (prednisone-2-12). Methods: 223 patients from the Registro Espanol de Lupus Eritematoso Sisternico inception cohort were studied. The cumulative dose of prednisone-1 and prednisone-2-12 were calculated and recoded into a four-level categorical variable: no prednisone, low dose (up to 7.5 mg/day), medium dose (up to 30 mg/day) and high dose (over 30 mg/day). The association between the cumulative prednisone-1 and prednisone-2-12 doses was tested. We analysed whether the four level prednisone-1 categorical variable was an independent predictor of an average dose >7.5 mg/day of prednisone-2-12. Adjusting variables included age, immunosuppressives, antimalarials, methyl-prednisolone pulses, lupus nephritis and baseline SLE Disease Activity Index (SLEDAI). Results: Within the first month, 113 patients (51%) did not receive any prednisone, 24 patients (11%) received average low doses, 46 patients (21%) received medium doses and 40 patients (18%) received high doses. There was a strong association between prednisone-1 and prednisone-2-12 dose categories (p7.5 mg/day, while patients receiving low dose prednisone-1 were not (adjusted OR 1.4, 95% CI 0. 0.38 to 5.2). If the analysis was restricted to the 158 patients with a baseline SLEDAI of >= 6, the model did not change. Conclusion: The dose of prednisone during the first month after the diagnosis of SLE is an independent predictor of prednisone burden during the following 11 months., This study was supported by the Spanish Society of Internal Medicine.

Published
2016
Full Text
View/download PDF

2. Mild presentation of systemic lupus erythematosus in elderly patients assessed by SLEDAI.

Author

Formiga, F, Moga, I, Pac, M, Mitjavila, F, Rivera, A, and Pujol, R

Subjects
SYSTEMIC lupus erythematosus, DNA, DISEASES in older people, IMMUNOLOGY, PATIENTS
Abstract

Objective: Systemic lupus erythematosus (SLE) predominantly affects young patients. SLE starting in later life has a clinical presentation different than in younger patients. We have used the SLE Disease Activity Index (SLEDAI) to explore the relationship between age of onset and disease activity. Methods: We selected all patients controlled in our hospital at the moment of clinical diagnosis of SLE (100 patients; 85 females and 15 males). They were classified in two groups: those with early onset (<50 y) and those with late onset (>50 y) based on their age at the moment of clinical diagnosis of SLE. Results: In 12 patients the onset of SLE was > 50 y (10 females and two males; mean age 59 y). The early onset patients had significantly higher SLEDAI values at the presentation and during the first year of disease with respect to elderly patients. Antibodies to DNA and hypocomplementemia were detected more often in younger patients. Conclusion: Our results confirm using SLEDAI, that the lupus of the elderly patients is a distinct clinical subgroup with a milder course of disease. [ABSTRACT FROM AUTHOR]

Published
1999
Full Text
View/download PDF

3. The Hidden Side of Complement Regulator C4BP: Dissection and Evaluation of Its Immunomodulatory Activity

Author

Inmaculada Serrano, Ana Luque, Francesca Mitjavila, Anna M. Blom, Santiago Rodríguez de Córdoba, M. Cristina Vega, Joan Torras, Josep M. Aran, Generalitat de Catalunya, Ministerio de Ciencia, Innovación y Universidades (España), Instituto de Salud Carlos III, European Commission, Ministerio de Economía y Competitividad (España), Comunidad de Madrid, Luque, Ana [0000-0001-9612-3926], Mitjavila, F. [0000-0002-4340-6989], Blom, Anna M. [0000-0002-1348-1734], Rodríguez de Córdoba, Santiago [0000-0001-6401-1874], Vega, María Cristina [0000-0003-0628-8378], Aran, Josep M. [0000-0003-2827-9392], Luque, Ana, Mitjavila, F., Blom, Anna M., Rodríguez de Córdoba, Santiago, Vega, María Cristina, and Aran, Josep M.

Subjects
Inflammation, C4BP(b-), Immunoregulació, Complement C4b-Binding Protein, Immunology, Lupus, Immunoregulation, chemical and pharmacologic phenomena, Dendritic cells, Monocytes, Immunomodulation, Lupus nephritis, PRP6-HO7, Immunology and Allergy, Cytokines, Humans
Abstract

16 p.-9 fig., C4b-binding protein (C4BP) is a well-known regulator of the complement system that holds additional and important activities unrelated to complement inhibition. Recently, we have described a novel immunomodulatory activity in the minor C4BP(β-) isoform directly acting over inflammatory phagocytes. Here we show that incorporation of the β-chain to the C4BP α-chain oligomer interferes with this immunomodulatory activity of C4BP. Moreover, an oligomeric form including only the complement control protein 6 (CCP6) domain of the C4BP α-chain (PRP6-HO7) is sufficient to “reprogram” monocyte-derived DCs (Mo-DCs) from a pro-inflammatory and immunogenic phenotype to an anti-inflammatory and tolerogenic state. PRP6-HO7 lacks complement regulatory activity but retains full immunomodulatory activity over inflammatory Mo-DCs induced by TLRs, characterized by downregulation of relevant surface markers such as CD83, HLA-DR, co-stimulatory molecules such as CD86, CD80 and CD40, and pro-inflammatory cytokines such as IL-12 and TNF-α. Furthermore, PRP6-HO7-treated Mo-DCs shows increased endocytosis, significantly reduced CCR7 expression and CCL21-mediated chemotaxis, and prevents T cell alloproliferation. Finally, PRP6-HO7 shows also full immunomodulatory activity over Mo-DCs isolated from lupus nephritis patients with active disease, even without further pro-inflammatory stimulation. Therefore PRP6-HO7, retaining the immunomodulatory activity of C4BP(β-) and lacking its complement regulatory activity, might represent a promising and novel alternative to treat autoimmune diseases., We thank CERCA Programme/Generalitat de Catalunya for institutional support. This work was supported by the Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain) (grants FIS-ISCIII PI20/00464, PI16/00377 and DTS20/00016), and the “Departament de Recerca i Universitats de la Generalitat de Catalunya” (grants 2019PROD00081 and 2017SGR291), all co-funded by FEDER funds/European Regional Development Fund (ERDF)-a way to build Europe-. Dr. Vega is supported by the Spanish “Ministerio de Ciencia, Innovación y Universidades/FEDER” [RTI2018-102242-B-I00]. Dr. Rodriguez de Córdoba is supported by the Spanish “Ministerio de Economia y Competitividad/FEDER [SAF2015-66287-R]. Dr. Vega and Dr. Rodriguez de Córdoba are also funded by the Autonomous Region of Madrid [S2017/BMD-3673] and the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) [SGL2103020].

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results